Global Binge-eating Disorder Treatment Market 2024-2028

Global Binge-Eating Disorder Treatment Market 2024-2028

The binge-eating disorder treatment market is forecasted to grow by USD 568.7 mn during 2023-2028, accelerating at a CAGR of 6.78% during the forecast period. The report on the binge-eating disorder treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of binge-eating disorder, growing obese population, and rising government initiatives.

Technavio's binge-eating disorder treatment market is segmented as below:

By Distribution Channel

• Offline
• Online

By Type

• Antidepressants
• Anticonvulsants
• Stimulants and others

By Geography

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the development and approval of new drugs as one of the prime reasons driving the binge-eating disorder treatment market growth during the next few years. Also, increasing preference for partial hospitalization program (php) and emergence of virtual telemedicine will lead to sizable demand in the market.

The report on the binge-eating disorder treatment market covers the following areas:

• Binge-eating disorder treatment market sizing
• Binge-eating disorder treatment market forecast
• Binge-eating disorder treatment market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading binge-eating disorder treatment market vendors that include Alvogen Iceland ehf, Bausch Health Companies Inc., Chronos Therapeutics Ltd., Currax Pharmaceuticals LLC, Eli Lilly and Co., Johnson and Johnson Services Inc., Lupin Ltd., Omeros Corp., Pyramid Healthcare Inc., Rosewood Centers for Eating disorders, Sumitomo Pharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Timberline Knolls Residential Treatment Center, Tonix Pharmaceuticals Holding Corp., Tryp Therapeutics Inc., Viatris Inc., VIVUS LLC, and Walden Behavioral Care. Also, the binge-eating disorder treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.